AN2 Therapeutics (ANTX) director receives 2,789-share stock grant in lieu of cash

Rhea-AI Filing Summary

Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.

AN2 Therapeutics, Inc. director Gilbert Lynn Marks received a grant of 2,789 shares of Common Stock on July 10, 2026. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and vest immediately. Following this award, Marks directly holds 81,873 shares of Common Stock.

Insights

Corporate governance analyst

Routine stock grant replacing cash fees; neutral governance event.

Director Gilbert Lynn Marks received 2,789 shares of AN2 Therapeutics common stock for board service on July 10, 2026. The grant was made at a stated price of $0.00 per share as equity compensation rather than cash.

The footnote clarifies these shares were issued in lieu of cash under the non-employee director compensation policy and vest immediately, indicating no ongoing vesting risk. After the grant, Marks directly holds 81,873 shares, showing continued equity exposure but no open-market buying or selling.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Marks Gilbert Lynn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,789	$0.00	--

Holdings After Transaction: Common Stock — 81,873 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 2,789 shares of Common Stock Price per share: $0.0000 Total shares after transaction: 81,873 shares

3 metrics

Shares granted 2,789 shares of Common Stock Equity issued in lieu of cash compensation to director on July 10, 2026

Price per share $0.0000 Stated transaction price for the 2,789-share stock award

Total shares after transaction 81,873 shares Director Gilbert Lynn Marks’ direct holdings following the grant

Key Terms

non-employee director compensation policy, in lieu of cash compensation, vest immediately

3 terms

non-employee director compensation policy financial

"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy."

in lieu of cash compensation financial

"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy."

vest immediately financial

"All shares vest immediately."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 07:41 PM Accepted by SEC EDGAR 07/10/2026 - 07:41 PM Learn about SEC filing dates

FAQ

What did AN2 Therapeutics (ANTX) director Gilbert Lynn Marks report in this Form 4?

Director Gilbert Lynn Marks reported receiving 2,789 shares of AN2 Therapeutics common stock on July 10, 2026. These shares were issued as equity compensation in place of cash fees and vest immediately.

How many AN2 Therapeutics (ANTX) shares does Gilbert Lynn Marks hold after this transaction?

After the grant, Gilbert Lynn Marks directly holds 81,873 shares of AN2 Therapeutics common stock. This total reflects his updated direct ownership following receipt of 2,789 shares in lieu of cash compensation.

Was the AN2 Therapeutics (ANTX) Form 4 transaction a market purchase or sale?

No, the Form 4 reports a grant/award acquisition of 2,789 shares, not a market purchase or sale. The shares were issued at $0.00 per share as stock compensation for director services.

Why did AN2 Therapeutics (ANTX) issue 2,789 shares to director Gilbert Lynn Marks?

The 2,789 shares were issued to Gilbert Lynn Marks in lieu of cash compensation under AN2 Therapeutics’ non-employee director compensation policy. This reflects the company’s practice of paying part of director fees in stock.

Do the new AN2 Therapeutics (ANTX) shares granted to Gilbert Lynn Marks vest over time?

No. According to the footnote, all 2,789 shares vest immediately. There is no multi-year vesting schedule attached to this stock grant made under the non-employee director compensation policy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marks Gilbert Lynn

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		A		2,789(1)	A	$0	81,873	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

	/s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)